Cardiokinetix parachute device study

CardioKinetix Reaches Half Enrollment for Parachute Device ...

★ ★ ★ ★ ★

1/15/2016 · Multidisciplinary heart team evaluating patients for enrollment in study of catheter-based heart failure device. CardioKinetix Inc. announced that it has enrolled more than half of the subjects in its pivotal United States trial, PARACHUTE IV. ... CardioKinetix Reaches Half Enrollment for Parachute Device U.S. Pivotal Trial.

CardioKinetix Reaches Half Enrollment for Parachute Device ...

A Multinational Trial To Evaluate The Parachute Implant ...

★ ★ ★ ★ ☆

1/31/2011 · With this background, CardioKinetix has developed a catheter-based intravascular approach to ventricular partitioning using an implantable device. The purpose of this study is to assess the safety of using the CardioKinetix Parachute device to isolate the malfunctioning portion of the left ventricle in patients with symptoms of HF due to ...

A Multinational Trial To Evaluate The Parachute Implant ...

Cardiokinetix

★ ★ ★ ★ ★

We would like to show you a description here but the site won’t allow us.

Cardiokinetix

A Pivotal Trial to Establish the Efficacy and Long-term ...

★ ★ ★ ★ ★

6/8/2012 · Device: CardioKinetix Parachute Implant and All Appropriate Medical Therapy (AAMT) CardioKinetix Parachute implant and all appropriate medical therapy. ... To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

A Pivotal Trial to Establish the Efficacy and Long-term ...

Percutaneous Ventricular Restoration Therapy Using the ...

★ ★ ☆ ☆ ☆

9/5/2016 · Study design. The Percutaneous Ventricular Restoration in Chronic Heart Failure due to Ischemic Heart Disease (PARACHUTE) China study was a prospective, nonrandomized, observational study conducted in seven medical centers in China designed to assess safety and efficacy of the Parachute device.

Percutaneous Ventricular Restoration Therapy Using the ...

CardioKinetix Releases One-Year Clinical Data From ...

★ ★ ★ ★ ★

CardioKinetix Inc. announced results of a pooled analysis study of the catheter-based Parachute ventricular partitioning device. Twelve-month clinical data from PARACHUTE III, a study of 100 ... CardioKinetix Releases One-Year Clinical Data From PARACHUTE III Trial.

CardioKinetix Releases One-Year Clinical Data From ...

Novel Catheter-Based Treatment for Heart Failure Begins U ...

★ ★ ★ ★ ☆

February 6, 2013 --CardioKinetix, Inc., a medical device company, based in Menlo Park, California, recently announced the start of a major U.S.-based trial for their Parachute™ Ventricular Partitioning Device, the first catheter-based treatment for heart failure. Implanted in a procedure similar ...

Novel Catheter-Based Treatment for Heart Failure Begins U ...

CardioKinetix Initiates Study in China of First-of-Its ...

★ ★ ☆ ☆ ☆

10/23/2014 · “The initiation of the China study is a major milestone for CardioKinetix,” said Maria Sainz, president and CEO of CardioKinetix. “We are proud of our efforts to bring the Parachute ...

CardioKinetix Initiates Study in China of First-of-Its ...

CardioKinetix reports meta-analysis study results of ...

★ ★ ☆ ☆ ☆

5/23/2013 · CardioKinetix Inc., a medical device company pioneering a catheter-based treatment for heart failure, today announced results of a meta-analysis study of the first-of-its-kind catheter-based ...

CardioKinetix reports meta-analysis study results of ...

CardioKinetix Announces the 500th Parachute Heart Failure ...

★ ★ ★ ★ ★

7/21/2016 · CardioKinetix Inc., a medical device company pioneering a catheter-based treatment for heart failure, today announced that 500 patients have received ... The company’s U.S. pivotal study ...

CardioKinetix Announces the 500th Parachute Heart Failure ...

CardioKinetix targets FDA approval with heart-failure ...

★ ★ ☆ ☆ ☆

1/8/2013 · CardioKinetix, a 2012 Fierce 15 winner, has launched a pivotal trial for its Parachute Ventricular Partitioning Device, planning to amass enough …

CardioKinetix targets FDA approval with heart-failure ...

CardioKinetix Inc. Archives - MassDevice

★ ★ ★ ★ ★

5/14/2018 · CardioKinetix made strides in research for its novel Parachute catheter-based left ventricle implant, which proved promising after 2 years in study results unveiled at this year’s EuroPCR ...

CardioKinetix Inc. Archives - MassDevice

CardioKinetix Inc. Initiates Study In China Of First-Of ...

★ ★ ★ ☆ ☆

10/23/2014 · CardioKinetix Inc. Initiates Study In China Of First-Of-Its-Kind Parachute Device For Treatment Of Heart Failure - read this article along with other careers information, tips …

CardioKinetix Inc. Initiates Study In China Of First-Of ...

Patient-specific finite element modeling of the ...

★ ★ ★ ★ ★

The Parachute ® (Cardiokinetix, Inc., Menlo Park, California) is a catheter-based device intended to reverse left ventricular (LV) remodeling after antero-apical myocardial infarction. When deployed, the device partitions the LV into upper and lower chambers. To simulate its mechanical effects, we created a finite element LV model based on computed tomography (CT) images from a patient before ...

Patient-specific finite element modeling of the ...

CardioKinetix commences Parachute Ventricular Partitioning ...

★ ★ ☆ ☆ ☆

6/7/2012 · CardioKinetix Inc., a medical device company pioneering a catheter-based treatment for heart failure, announced today that it has begun enrollment in PARACHUTE III, a post-market safety ...

CardioKinetix commences Parachute Ventricular Partitioning ...

CardioKinetix shows favorable results from Parachute ...

★ ★ ★ ★ ★

The Parachute is a catheter based partitioning device featuring a fluoropolymer (ePTFE) membrane stretched over a nitinol frame. It is placed within the left ventricle for patients who. Compelo Medical Devices - Latest industry news and analysis is using cookies.

CardioKinetix shows favorable results from Parachute ...

PARACHUTE IV Percutaneous Ventricular Restoration in ...

★ ★ ☆ ☆ ☆

Detailed Study Description. 1.0 INTRODUCTION . CardioKinetix has developed a catheter-based treatment for patients with left ventricular dilation after an anterior MI. The implantable device, called the Parachute Implant, is a partitioning membrane deployed within the compromised ventricle.

PARACHUTE IV Percutaneous Ventricular Restoration in ...

First Report of a Confirmatory (Cohort B) Study of the ...

★ ★ ★ ★ ★

Study of the Parachute Device in Ischemic Dilated Cardiomyopathy Martyn R. Thomas, MD St. Thomas’ Hospital London, United Kingdom. Disclosure Statement of Financial Interest ... The Parachute™ device is comprised of a fluoropolymer (ePTFE) membrane stretched over a nitinol frame

First Report of a Confirmatory (Cohort B) Study of the ...

CardioKinetix debuts Parachute device in China - MassDevice

★ ★ ★ ★ ☆

CardioKinetix said its Parachute ventricular partitioning device was used to treat 2 patients in Beijing. The Parachute device is used to restore damage to the left ventricle after a heart attack ...

CardioKinetix debuts Parachute device in China - MassDevice

Efficacy and Safety of PARACHUTE® Device - researchgate.net

★ ★ ★ ☆ ☆

Efficacy and Safety of PARACHUTE® Device - researchgate.net

Efficacy and Safety of PARACHUTE® Device - researchgate.net

Studies Open to Enrollment | Cardiology | Weill Cornell ...

★ ★ ★ ★ ★

Studies Open to Enrollment. ... The purpose of the study is to assess the efficacy and long-term safety of the CardioKinetix Parachute device, an umbrella-shaped membrane that is is implanted inside the left ventricle of the heart. ... and the presence of the implanted ASO device. Study subjects will be followed up for 12 months after the ...

Studies Open to Enrollment | Cardiology | Weill Cornell ...

Edwards gains option to acquire startup CardioKinetix in ...

★ ★ ★ ★ ☆

12/8/2014 · Edwards Lifesciences led a $50 million financing for catheter-based heart failure treatment startup CardioKinetix. The cash is expected to enable the completion of an ongoing U.S. pivotal trial ...

Edwards gains option to acquire startup CardioKinetix in ...

TCT-441 A Pathologic Study of Explanted Parachute Devices ...

★ ★ ☆ ☆ ☆

10/29/2013 · The Parachute(r) (CardioKinetix Inc., Menlo Park, CA) partitions the left ventricle excluding the scarred myocardium from functioning myocardium, and has shown promise in clinical studies as an adjunctive interventional treatment for heart failure (HF). We sought to evaluate the pathologic findings

TCT-441 A Pathologic Study of Explanted Parachute Devices ...

Percutaneous Implantation of A Parachute Device For ...

★ ★ ★ ★ ★

Recently, a novel percutaneous implantable device, the Parachute LV partitioning device (Cardiokinetix, Inc., Menlo Park, CA) has been developed to isolate the dysfunctional anteroapical region of the LV, reduce both systolic and diastolic volumes, decrease myocardial wall stress, and improve LV hemodynamics as well as functional capacity.

Percutaneous Implantation of A Parachute Device For ...

Percutaneous Ventricular Restoration in Chronic Heart ...

★ ★ ★ ★ ★

Percutaneous Ventricular Restoration in Chronic Heart Failure Due to Ischemic Heart Disease Clinical Trial Details The purpose of the study is to assess the efficacy and long-term safety of the CardioKinetix Parachute device, an umbrella-shaped membrane that is is implanted inside the left ventricle of the heart.

Percutaneous Ventricular Restoration in Chronic Heart ...
Triandis-study-guide.html,Tricc-study-pdf.html,Triforce-marker-study-chelmsford.html,Tsbp-pharmacy-law-study.html,Tsi-test-study-guide-pdf.html